Enovis Corp Stock Price, News & Analysis

Enovis (NYSE:ENOV) reported strong Q2 2025 financial results with net sales of $565 million, representing a 7% reported growth and 5% organic growth year-over-year. The company's Reconstructive segment grew 11% on a reported basis, while Prevention & Recovery (P&R) increased 5%.

Despite positive sales growth, Enovis recorded a net loss of $37 million (6.5% of sales) and adjusted EBITDA of $97 million (17.2% of sales). The company updated its 2025 guidance, raising revenue expectations to $2.245-2.275 billion and adjusted EPS guidance to $3.05-3.20.

Enovis Corporation (NYSE: ENOV), a medical technology growth company, will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. ET. The company will release its earnings report earlier that morning.

Investors can access the live webcast through Enovis' website investor section, and those wishing to participate in the call can dial (833) 685-0901. A presentation and replay of the call will be available on the company's website following the event.

Enovis Corporation (NYSE: ENOV), a medical technology growth company, announced its management team's participation in two upcoming investor conferences. Chief Financial Officer Ben Berry will lead a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10th at 2:00 p.m. Eastern Time. Additionally, Berry will participate in investor meetings at the Citizens Medical Devices and Healthcare Services Forum on June 17th. Live audio webcasts and replays of these events, when available, will be accessible through the Investors section of the company's website under Events and Presentations.

Enovis Corporation (NYSE: ENOV) reported strong Q1 2025 financial results with net sales of $559 million, representing an 8% growth on a reported basis and 9% on a comparable basis. The company's Reconstructive segment showed impressive growth of 11% year-over-year, while P&R segment grew 5%. However, Enovis reported a net loss from continuing operations of $56 million (-$0.98 per share).

The company achieved an adjusted EBITDA of $99 million (17.7% of sales), marking a 160 basis point improvement from the previous year. Enovis updated its 2025 guidance, raising revenue expectations to $2.22-2.25 billion but lowering adjusted EBITDA forecast to $385-395 million due to $20 million in tariff-related impact. The company also announced the appointment of Damien McDonald as CEO, effective May 12th, 2025.

Enovis (NYSE: ENOV) has announced it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time. The company will release its earnings press release earlier that morning. A presentation and webcast will be accessible through the 'Investors' section of Enovis' website.

Investors can participate by dialing (833) 335-0887 with Access Code: 482081, or preregister through a provided link. A replay of the call will be made available on the company's website later that day.

Enovis (NYSE: ENOV) has announced the appointment of Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald, who brings over 35 years of medical device industry experience, will succeed Matt Trerotola, who is retiring. McDonald will also join the Enovis Board of Directors after the 2025 Annual Meeting on May 21.

McDonald previously served as CEO of LivaNova, where he improved growth, profitability, and shareholder value. His experience includes leadership roles at Danaher, Zimmer, and Johnson & Johnson's Ethicon unit. The company has reiterated its Q1 2025 guidance with expected revenues of $555-563 million and adjusted EBITDA of $97-100 million.

Sharon Wienbar, currently Lead Independent Director, will become Board Chair following Trerotola's retirement. The company will address questions about the transition during its Q1 2025 earnings call on May 8, 2025.

Enovis (NYSE: ENOV) will showcase its expanding foot and ankle solutions portfolio at the ACFAS Annual Scientific Conference in Phoenix from March 27-30, 2025. The company will highlight several innovative products, including the new Tarsoplasty Percutaneous Lapidus Correction System for bunionectomy procedures.

The exhibition will feature advanced solutions such as OssiGraft Prime viable bone matrix allografts, Aircast AirSelect Elite pneumatic walking boot, Velocity+ proximal extension cuff, and Regeneration OL1000 bone growth stimulator. New research comparing the Arsenal Foot Plating System's screw angulation will also be presented.

The company will host two special events: 'Phoenix Rising: Foot & Ankle Edition' on March 28 and a Flatfoot/MIS Techniques Workshop on March 26.

Enovis (NYSE: ENOV) has announced its management team's participation in three upcoming investor conferences in March and April 2025. The schedule includes:

• Canaccord Genuity Musculoskeletal Conference: CFO Ben Berry and Recon Group President Louie Vogt will join a fireside chat on March 10th at 10:00 a.m. PT
• 37th Annual Roth Conference: Recon Group President Louie Vogt will participate in a fireside chat on March 17th at 8:30 a.m. PT
• 24th Annual Needham Healthcare Conference: CFO Ben Berry will engage in a fireside chat on April 8th at 1:30 p.m. ET

Live audio webcasts and replays will be accessible through the Investors tab under Events and Presentations on the company's website.

Enovis (NYSE: ENOV) reported strong Q4 2024 results with net sales of $561 million, up 23% year-over-year and 6% on comparable sales basis. The company's Reconstructive segment showed impressive growth of 59% reported (10% comparable), while Prevention & Recovery grew 2% reported (3% comparable).

However, Enovis reported a significant Q4 net loss from continuing operations of $704 million, primarily due to a $645 million non-cash goodwill impairment charge. Q4 adjusted EBITDA reached $113 million (20% of sales), showing 210 basis points improvement year-over-year.

For full-year 2024, net sales grew to $2.1 billion, up 23% reported and 6% comparable. The company provided 2025 guidance expecting revenue of $2.19-2.22 billion with 6-6.5% organic growth and adjusted EBITDA of $405-415 million. CEO Matt Trerotola announced his planned retirement, with a succession process underway.